Breast Cancer Clinical Trial
BrUOG 291: Five Fraction Partial Breast Irradiation Using Non-invasive Image-guided Breast Brachytherapy (NIBB)
Summary
To evaluate safety of 5 fraction accelerated partial brest irradiation in more convenient 5 fraction schedule.
Full Description
The purpose of this study is to evaluate the rate of early and intermediate toxicity related to accelerated partial breast irradiation (APBI) delivered in a more convenient 5 fraction schedule using non-invasive image-guided breast brachytherapy (NIBB) (AccuBoost System) in women with resected, early stage breast cancer.
Non-invasive image-guided breast brachytherapy (NIBB), using advanced image-guided radiation technology, has the potential to eliminate the disadvantages of the conventional APBI techniques. NIBB facilitates non-invasive partial breast irradiation without the use of catheters or implants. Yet by using breast immobilization and precise image-guidance, it reduces non-target breast tissue within the irradiated field compared with other non-invasive APBI techniques such as 3D-CRT. This has made NIBB an attractive approach to deliver APBI.
We hypothesize that NIBB delivered in 5 treatments will be a more convenient, safe and effective modality to deliver partial breast irradiation.
Anticipated advantages of NIBB protocol treatment include:
Convenient treatment schedule
Short course can allow for increased patient access to treatment
Non-invasive approach
Increased accuracy with precise targeting of lumpectomy cavity using advanced imaging
Reduced irradiation of non-target breast tissue
Reduced skin toxicity
No heart or lung radiation exposure
Reduced late skin or breast toxicity
High rate of good or excellent cosmetic outcome
High rate of ipsilateral breast tumor control comparable to other APBI techniques
Eligibility Criteria
Inclusion Criteria:
A confirmed histological diagnosis of invasive breast carcinoma or DCIS;
Age greater or equal to 50 years old;
Life expectancy > 6 months;
Treated by breast conserving surgery
Pathologic lymph node negative, which includes (pN0 i-, i+);
Patients, who are at very low risk for sentinel node involvement and sentinel node biopsy is not performed, are eligible if the treating investigator documents clinically lymph node negative (cN0). These patients include:
DCIS
Microinvasion only
Pure tubular or mucinous histology
Patients ≥ 70yo with T1a-T1c; estrogen receptor +
Pathologic tumor size
less than or equal to 2 cm for invasive disease;
less than or equal to 3 cm for DCIS;
Estrogen receptor positive if invasive disease (DCIS can be ER negative)
Negative surgical margins greater than or equal to 2 mm. A margin of <2mm is acceptable if at natural boundary, i.e. skin or pectoralis fascia.
No lymphovascular invasion;
ECOG performance status of 0-2 (Appendix 1);
Informed consent signed.
Exclusion Criteria:
Known BRCA 1/2 Mutation; (BRCA 1 and 2 testing is not required)
Active lupus or scleraderma;
Pregnancy;
Psychiatric or addictive disorder that would preclude attending follow-up;
Neoadjuvant chemotherapy (adjuvant chemotherapy is permitted);
Suspicious remaining microcalcification on post-surgery mammogram (unless biopsy proven benign);
pN+ on axillary dissection or in the sentinel lymph node biopsy (N0i+ are considered node negative and are not excluded);
Multicentric disease;
Paget's disease of the nipple;
Breast Implants
Distant metastases;
Lumpectomy cavity not well visualized on AccuBoost imaging;
Lumpectomy cavity with 1cm margin (CTV/PTV) not adequately encompassed by any available applicator.
Breast separation with compression > 8cm at time of simulation.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 3 Locations for this study
La Jolla California, 92093, United States
Lakeland Florida, 33805, United States
Providence Rhode Island, 02903, United States
How clear is this clinincal trial information?

Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.